“Pricing is key — it’s not really too innovative, but you’ve
always got to stay in front of each game to make sure you’re pricing
aggressively and getting the most value out of your PBM relationship.”
— Brian Anderson, a principal at Milliman, Inc., talked with
AIS's Radar on Drug Benefits about innovations that may rise from Cigna Corp.'s
acquisition of Express Scripts.
No comments:
Post a Comment